Logo Logo

Yearly Archives: "2018"

  1. Home
  2. 2018
Dec 18, 2018
FDA accepts BrainStorm’s NurOwn® IND application for progressive multiple sclerosis
INforMS
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative [...]
Elizabeth Porco
Read More
...33
0
Oct 12, 2018
Positive late-breaking phase II data evaluating investigational oral therapy
INforMS
First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) [...]
Elizabeth Porco
Read More
...29
0
Oct 11, 2018
TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS
INforMS, Partners
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]
Elizabeth Porco
Read More
...34
0
Oct 10, 2018
Novartis announces FDA filing acceptance of Siponimod (BAF312)
INforMS, Partners
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating [...]
Elizabeth Porco
Read More
...36
0
Oct 10, 2018
New efficacy and safety data on multiple sclerosis portfolio to be presented
INforMS, Partners
​Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show [...]
Elizabeth Porco
Read More
...34
0
Oct 10, 2018
Press release – Ocrevus data show early initiation reduces progression
INforMS, Partners
Dear Advocates, OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in [...]
Elizabeth Porco
Read More
...31
0
Sep 28, 2018
Our condolences to the family of Nicola “Nicki” Ward-Abel, RGN, BSc (Hons), MSCN
CMSC PR
It is with a heavy heart that IOMSN announces the passing of Nicola "Nicki" Ward-Abel. Nicki was a founding member of IOMSN via our UK [...]
Elizabeth Porco
Read More
...36
0
Sep 12, 2018
Novartis announces PARADIGMS study demonstrating benefit of Gilenya®
INforMS, Partners
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents [...]
Elizabeth Porco
Read More
...29
0
Sep 05, 2018
Researchers identify new subtype of multiple sclerosis
INforMS
Researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the disease and potentially [...]
Elizabeth Porco
Read More
...38
0
Aug 29, 2018
MRI tests may help doctors predict multiple sclerosis progression in patients
INforMS, MS Community
Researchers have apparently found a way to help predict multiple sclerosis disease progression one year after an initial [...]
Elizabeth Porco
Read More
...32
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM